Averill Holds 2.309M Shares (4.5%) as Suvretta and Cowen Report 5.2% Stakes
Rhea-AI Filing Summary
A Schedule 13G/A reports that Suvretta Capital Management, LLC and Aaron Cowen each disclose beneficial ownership of 2,676,000 shares of Abeona Therapeutics common stock, representing 5.2% of the class, while Averill Master Fund, Ltd. holds 2,309,267 shares ( 4.5% ). Each reporting person shows zero sole voting or dispositive power and reports the corresponding amounts as shared voting and dispositive power. The filers state the securities are directly owned by advisory clients of Suvretta and that the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Positive
- Clear disclosure of holdings with exact share counts and percentages for Suvretta, Aaron Cowen, and Averill.
- Filers certify holdings were acquired and are held in the ordinary course, indicating passive intent per the filing.
- Includes Joint Filing Agreement and Control Person Identification exhibits, supporting legal completeness of the disclosure.
Negative
- No sole voting or dispositive power reported, indicating the filers do not claim direct control over corporate decisions.
- Filing notes the securities are directly owned by advisory clients of Suvretta while Suvretta and Aaron Cowen each report >5% (5.2%), which creates an internal reporting nuance about attribution of beneficial ownership.
Insights
TL;DR: Passive institutional stakes disclosed: Suvretta/Cowen 2.676M shares (5.2%), Averill 2.309M shares (4.5%), all reported as shared power.
The filing is a Schedule 13G/A disclosure showing material, passive ownership positions in Abeona (ABEO). The key metrics are explicit: Suvretta Capital Management and Aaron Cowen each report 2,676,000 shares (5.2%), and Averill Master Fund reports 2,309,267 shares (4.5%). All three report no sole voting or dispositive power and claim holdings are held in the ordinary course, consistent with a non-activist position. For investors, the filing increases transparency about substantial holders but, on its face, does not indicate an intent to influence company control.
TL;DR: Disclosure includes joint-filing exhibits and a disclaimer that securities are owned by advisory clients, with shared rather than sole control.
The document includes Exhibit A (Joint Filing Agreement) and Exhibit B (Control Person Identification) and signatures from authorized signatories. Filers explicitly disclaim beneficial ownership beyond pecuniary interest and emphasize advisory-client ownership for Suvretta. The reporting shows shared voting and dispositive authority, which is relevant to governance assessments because it indicates collective influence rather than direct control by a single reporting person. The filing therefore documents meaningful stake levels without asserting takeover intent.